Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-center, Double-blind, Randomized, Placebo- and Positive-controlled, Parallel-group With Nested Cross-over, Multiple-dose, Up-titration Study of the Effects of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects

NCT02206204 is registered in ClinicalTrials.gov with Actelion as lead sponsor.

NCT NCT02206204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02206204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-center, Double-blind, Randomized, Placebo- and Positive-controlled, Parallel-group With Nested Cross-over, Multiple-dose, Up-titration Study of the Effects of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects
Lead sponsor
Actelion
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2012
Completion date
November 30, 2012
Enrollment
159 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiodynamics, pharmacokinetics, safety, tolerability